EUVIMEDEUVIMED entdecken
Crossref

Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy

Philip Macilwraith iD, Mark Shackleton iD, Andrew Haydon iD, David Nadebaum iD, Victoria Mar iD, Vivek Naranbhai iD, Martin H Cherk

Journal of Medical Imaging and Radiation Oncology · 2026

DOI: 10.1111/1754-9485.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2026. Verfasst von Philip Macilwraith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Melanoma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the incidence of pseudoprogression on 18 F‐FDG PET/CT scans in metastatic melanoma patients commencing immune checkpoint inhibitor therapy and to determine the average time to confirmed 18 F‐FDG PET/CT response in the pseudoprogression cohort identified.

Methods

Patients with metastatic melanoma who underwent baseline and follow‐up 18 F‐FDG PET/CT scans after commencing immune checkpoint inhibitor therapy at Alfred Hospital (2012–2023) were retrospectively reviewed. Cases of pseudoprogression were identified by a keyword search of reports and confirmed on image review by a nuclear medicine physician. Data on timing of confirmed response, immune‐related adverse events, and autoimmune history were also collected.

Results

10/401 (2.49%) metastatic melanoma patients were confirmed as having pseudoprogression on PET/CT. 8/10 (80%) had new FDG‐avid lesions and 2/10 (20%) had an increase in size and SUVmax of original disease. 8/10 (80%) of patients achieved complete metabolic remission on subsequent PET/CT scans with an average time to confirmed reduction of disease on PET/CT of 28.4 weeks. 4/10 (40%) received dual agent immunotherapy. 8/10 (80%) developed irAEs of varying types and severity. 2/10 (20%) had a history of pre‐existing autoimmune disease. 9/10 (90%) of pseudoprogression patients are alive at last review.

Conclusion

Pseudoprogression on 18 F‐FDG PET/CT occurred in approximately 2.5% of metastatic melanoma patients commencing immunotherapy with an average time to subsequent confirmed response of ~6 months. This highlights the importance of not ceasing immunotherapy prematurely based on early 18 F‐FDG PET/CT findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyMelanomaImmune Checkpoint InhibitorsImmunotherapyHumansFluorodeoxyglucose F18MaleFemaleRadiopharmaceuticalsMiddle AgedRetrospective StudiesAgedIncidenceDisease ProgressionAdultAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

FDG‐PETclinicalimmunotherapymetastatic melanomapseudoprogression

Substanzen

Fluorodeoxyglucose F18Immune Checkpoint InhibitorsRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Monash University, Melbourne, Victoria, Australia.
  • Department of Nuclear Medicine and PET, Alfred Hospital, Melbourne, Victoria, Australia.
  • Department of Dermatology, Alfred Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Philip Macilwraith, Mark Shackleton, Andrew Haydon, David Nadebaum, Victoria Mar, Vivek Naranbhai

Zitieren

APA

Macilwraith, P., Shackleton, M., Haydon, A., Nadebaum, D., Mar, V., Naranbhai, V., & Cherk, M. H. (2026). Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.70066

Vancouver

Macilwraith P, Shackleton M, Haydon A, Nadebaum D, Mar V, Naranbhai V, et al. Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy. Journal of Medical Imaging and Radiation Oncology. 2026. doi:10.1111/1754-9485.70066

BibTeX
@article{Macilwraith2026,
  author = {Macilwraith, Philip and Shackleton, Mark and Haydon, Andrew and Nadebaum, David and Mar, Victoria and Naranbhai, Vivek and Cherk, Martin H},
  title = {Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy},
  journal = {Journal of Medical Imaging and Radiation Oncology},
  year = {2026},
  doi = {10.1111/1754-9485.70066}
}
Kostenlos starten →